Two infusions of the investigational therapy CNP-104 safely reduced liver scarring (fibrosis) and led to beneficial changes in disease-related immune cell populations among adults with…
A researcher at the Virginia-Maryland College of Veterinary Medicine received a $2 million award from the National Institutes of Health (NIH) to continue research into…
Once daily treatment with oral ALG-055009 safely lowered levels of liver fat in people with metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty…
A U.S. Food and Drug Administration (FDA) advisory committee voted 10-1 that Ocaliva (obeticholic acid) doesn’t have a benefit-risk profile that would support its…
The American Liver Foundation (ALF) is granting its Spirit of Giving Family Award to a U.S. family for its dedication to raising funds and…
Researchers have uncovered the structure of the protein complex that allows the hepatitis C virus (HCV) to infect human cells, allowing them to reproduce and…
Advanz Pharma has secured a temporary suspension of a decision by the European Commission (EC) to revoke conditional approval of Ocaliva (obeticholic acid) for…
The Fatty Liver Alliance, a Canada-based advocacy group, is calling for supporters to sign a petition asking Madrigal Pharmaceuticals to apply to Canadian…
Researchers have detailed exactly how bemnifosbuvir — part of Atea Pharmaceuticals’ antiviral treatment combination for chronic hepatitis C infections — turns into the…
Treatment with direct-acting antivirals (DAAs) reduces the disease burden associated with liver scarring (fibrosis) and prevents severe liver outcomes and death among people with chronic…